Med Biogene (MBI) Hits New 52-Week Low at $0.03

Med Biogene Inc (CVE:MBI)’s share price reached a new 52-week low during trading on Monday . The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 0 shares trading hands. The stock had previously closed at C$0.03.

TRADEMARK VIOLATION NOTICE: “Med Biogene (MBI) Hits New 52-Week Low at $0.03” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at

Med Biogene Company Profile (CVE:MBI)

Med BioGene Inc, a life science company, focuses on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. Its products include the GeneFx Lung, a gene expression-based test for early-stage non-small-cell lung cancer that assists in identifying patients for adjuvant chemotherapy.

See Also: How prevalent are 12b-1 fees?

Receive News & Ratings for Med Biogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Med Biogene and related companies with's FREE daily email newsletter.

Leave a Reply